This chapter delves into the unique platforms such as adenoviral vectors and mRNA utilized by Johnson and Johnson, AstraZeneca, Moderna, and Pfizer for COVID-19 vaccines, emphasizing safety signals and unexpected adverse events. It discusses the positive impact of the vaccine rollout in reducing severe disease and saving lives, along with personal experiences and criticisms. The conversation also touches on vaccine mandates, economic externalities, transmission dynamics, and the challenges of eradicating the virus.